PREDICTING THE POTENTIAL FOR CANNABIDIOL INDUCED DRUG-DRUG INTERACTIONS WITH MAJOR CYP450 ENZYMES USING MODEL-BASED APPROACHES

被引：0
|
作者：
Eltanameli, B. [1 ]
Al Sahlawi, S. [1 ]
Cicali, B. [1 ]
Cristofoletti, R. [1 ]
机构：
[1] Univ Florida, Coll Pharm, Orlando, FL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
LB-032
引用
收藏
页码：S37 / S38
页数：2
相关论文
共 50 条
  • [21] Potential Metabolic Drug-Drug Interaction of Citrus aurantium L. (Rutaceae) Evaluating by Its Effect on 3 CYP450
    Zhou, Lu
    Cui, Man
    Zhao, Linlin
    Wang, Dongsheng
    Tang, Tao
    Wang, Wenbo
    Wang, Sheng
    Huang, Huiyong
    Qiu, Xinjian
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [22] EXPLANATION AND PREDICTION OF DRUG-INTERACTIONS WITH TOPIRAMATE USING A CYP450 INHIBITION SPECTRUM
    LEVY, RH
    BISHOP, F
    STREETER, AJ
    TRAGER, WF
    KUNZE, KL
    THUMMEL, KT
    MATHER, GG
    EPILEPSIA, 1995, 36 : 252 - 252
  • [23] Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug Interactions
    Umehara, Kenichi
    Cleary, Yumi
    Fowler, Stephen
    Parrott, Neil
    Tuerck, Dietrich
    DRUG METABOLISM AND DISPOSITION, 2022, 50 (03) : 214 - 223
  • [24] In Vitro CYP450 Enzyme Downregulation by GLP-1/Glucagon Coagonist Does Not Translate to Observed Drug-Drug Interactions in the Clinic
    Sall, Carolina
    Alifrangis, Lene
    Dahl, Kirsten
    Friedrichsen, Martin Haljeta
    Nygard, Sune Boris
    Kristensen, Kim
    DRUG METABOLISM AND DISPOSITION, 2022, 50 (08) : 1087 - 1097
  • [25] Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond
    Barton, Hugh A.
    Lai, Yurong
    Goosen, Theunis C.
    Jones, Hannah M.
    El-Kattan, Ayman F.
    Gosset, James R.
    Lin, Jian
    Varma, Manthena V.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (04) : 459 - 472
  • [26] Drug-Drug Interactions between COVID-19 and Tuberculosis Medications: A Comprehensive Review of CYP450 and Transporter-Mediated Effects
    Jony, M. Rasheduzzaman
    Ahn, Sangzin
    PHARMACEUTICALS, 2024, 17 (08)
  • [27] A DRUG-DRUG INTERACTION STUDY INVESTIGATING THE EFFECT OF GIVOSIRAN ON ACTIVITY OF FIVE DRUG METABOLIZING CYP450 ENZYMES IN ACUTE HEPATIC PORPHYRIA (AHP) PATIENTS.
    Agarwal, S.
    Sardh, E.
    Harper, P.
    Vassiliou, D.
    Simon, A.
    Robbie, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S59 - S59
  • [28] CYP450 activity inhibition by Guazuma ulmifolia and major phytochemical constituent, procyanidin β2 in vitro: assessing the potential for drug interactions
    Watson, J.
    Picking, D.
    Lamm, A.
    Delgoda, R.
    PLANTA MEDICA, 2019, 85 (18) : 1564 - 1564
  • [29] Assessment of the Potential for Drug-Drug Interactions Between INP104 and Gepants for Migraine Management Using a Model-based Approach
    Ray, Sutapa
    Torphy, Bradley
    Joshi, Shivang
    Vann, Robert
    Downing, Brett
    Fonseca, Daniella
    Shrewsbury, Stephen
    Aurora, Sheena
    NEUROLOGY, 2023, 100 (17)
  • [30] Assessment of the Potential for Drug-Drug Interactions Between INP104 and Gepants for Migraine Management Using a Model-based Approach
    Ray, S.
    Torphy, B.
    Joshi, S.
    Vann, R.
    Downing, B.
    Murphy, M.
    Fonseca, D.
    Shrewsbury, S.
    Aurora, S.
    HEADACHE, 2023, 63 : 1 - 1
12345